-
Mashup Score: 3
According to a poll conducted in 2021, 7·1% of the US population identifies as LGBTQI+, which is nearly double the percentage of the population a decade ago.1 This increase is likely to be a result of greater social acceptance and openness of individuals regarding sexual orientation and gender identity (SOGI).1 Specifically, although LGBTQI+ identification has been stable in older generations, it…
Categories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 1
The individual benefit of increasing adalimumab dose intervals versus the risk of disease recurrence is a trade-off that should take patient preferences regarding medication and the risk of a flare into account.
Categories: Gastroenterology, Latest HeadlinesTweet-
ICYMI, in our latest issue - Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial https://t.co/E6M4Wj4U7Z #gitwitter #crohns #ibd
-
-
Mashup Score: 0
Although sparse, available HIV and HCV incidence estimates offer insights into global levels of HIV and HCV transmission among PWID. Intensified efforts are needed to keep track of the HIV and HCV epidemics among PWID and to expand access to age-appropriate and gender-appropriate prevention services that serve young PWID and women who inject drugs.
Categories: Gastroenterology, Latest HeadlinesTweet-
New research - Artenie et al - Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis https://t.co/yIPtqE4ed1 #idtwitter #livertwitter #HIV #hepC #HCV #nohep #PWID @WHO https://t.co/PiQfE06HjF
-
-
Mashup Score: 0Status of HBV birth dose vaccination in Africa: the impact of COVID-19 and Gavi support on policy development - 1 year(s) ago
As a strategy to reach goals for hepatitis B virus (HBV) elimination by 2030, WHO recommends all newborn babies receive hepatitis B birth dose (HepB-BD) vaccine, preferably in the first 24 h of life.1 However, in 2021, only 17% of newborn babies in the WHO African region received a timely dose of HepB-BD vaccine. Of WHO regions, HepB-BD vaccination coverage is lowest in the African region; only…
Categories: Gastroenterology, Latest HeadlinesTweet-
New Comment - Njuguna et al - Status of HBV birth dose vaccination in #Africa: the impact of COVID-19 and Gavi support on policy development https://t.co/hbdI4XJLRF #HBV #HepB #nohep @GlobalHep @TFGH @gavi https://t.co/2nonLf5U2t
-
-
Mashup Score: 1Top 10 research priorities for irritable bowel syndrome: results of a James Lind Alliance priority setting partnership - 1 year(s) ago
Irritable bowel syndrome (IBS) is a highly prevalent, chronic disorder of gut–brain interaction (DGBI), characterised by abdominal pain in association with change in stool form or frequency.1 It affects 5% of the global population,2 and can be difficult to treat, affecting social functioning, ability to work, and quality of life.1 Impact on quality of life can be worse than other chronic diseases…
Categories: Gastroenterology, Latest HeadlinesTweet-
New Comment - Black et al - Top 10 research priorities for #irritablebowelsyndrome: results of a James Lind Alliance priority setting partnership https://t.co/rtNtn7IOrk #IBS #GITwitter @GutsCharityUK @BritSocGastro @DrCJBlack @alex_ford12399 @LindAlliance https://t.co/o8iLQBDFe1
-
-
Mashup Score: 1
A new analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. Although the number of cases in younger age groups is small, the uncertain causes of…
Categories: General Medicine Journals and Societies, Latest HeadlinesTweet-
RT @LancetGastroHep: New Editorial - Cause for concern: the rising incidence of early-onset pancreatic cancer https://t.co/1Nywxho4R5 #g…
-
-
Mashup Score: 1
A new analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. Although the number of cases in younger age groups is small, the uncertain causes of…
Categories: Gastroenterology, Latest HeadlinesTweet-
New Editorial - Cause for concern: the rising incidence of early-onset pancreatic cancer https://t.co/1Nywxho4R5 #gitwitter #pancreaticcancer https://t.co/f1zVQu2URw
-
-
Mashup Score: 3
Colesevelam was superior to placebo at inducing remission of bile acid diarrhoea diagnosed with C4 concentration greater than 46 ng/mL. Secondary outcome data suggest similar efficacy treating SeHCAT-defined bile acid diarrhoea. Colesevelam was safe during the treatment.
Categories: Gastroenterology, Latest HeadlinesTweet-
In our latest issue - the SINBAD trial, studying the efficacy and safety of colesevelam for the treatment of bile acid diarrhoea https://t.co/m1r0heRgjX #GITwitter #bad #diarrhoea #medtwitter
-
-
Mashup Score: 1
None of the single markers or multimarker scores achieved the predefined acceptable AUC for replacing biopsy in detecting people with both NASH and clinically significant fibrosis. However, several biomarkers could be applied in a prescreening strategy in clinical trial recruitment. The performance of promising markers will be further evaluated in the ongoing prospective LITMUS study cohort.
Categories: Gastroenterology, Latest HeadlinesTweet-
New research - Vali et al - Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study https://t.co/WGhWjp2heu #NASH #NAFLD #LiverTwitter @LITMUS_IMI https://t.co/DFfpPjRlWB
-
-
Mashup Score: 0
Data from this proof-of-concept study suggest that combination therapy with guselkumab and golimumab might be more effective for ulcerative colitis than therapy with either drug alone. These findings require confirmation in larger trials.
Categories: Gastroenterology, Latest HeadlinesTweet-
ICYMI - in our latest issue - the VEGA trial of guselkumab + golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis https://t.co/3Q4aVgziie #gitwitter #IBD #ulcerativecolitis
-
ICYMI, in our latest issue - Overcoming disparities for sexual and gender minority patients and providers in gastroenterology and hepatology: introduction to Rainbows in Gastro https://t.co/Lqn3Kl5sNL #gitwitter #livertwitter @RainbowinGastro #DEI